Introduction:
UK-based Semarion Ltd. has won the Ignite SME award at SLAS Europe 2024 in Barcelona for its innovative laboratory automation technology. Semarion’s Semacyte platform enables cells to be mobilized, aligned, and tracked using microcarriers without losing their morphology and function. The platform offers faster data generation, requires fewer cells for screenings, and allows for frozen storage.
- Semarion Ltd. won the Ignite SME award at SLAS Europe 2024 for its innovative laboratory automation technology.
- The Semacyte platform developed by Semarion allows for the mobilization, alignment, and tracking of cells using microcarriers.
- The platform enables faster data generation, requires fewer cells for screenings, and allows for frozen storage.
- Semarion’s technology addresses bottlenecks in rapid data generation and offers a significant increase in throughput and cost reduction to drug discovery workflows.
- Semarion is already working on projects with pharma companies and CROs and aims to launch its SemaCyte microcarrier platform on a commercial scale.
Conclusion:
Semarion Ltd. has been recognized for its innovative laboratory automation technology at the SLAS Europe 2024 event. The Semacyte platform offers significant improvements in data generation, workflow efficiency, and cost reduction in drug discovery processes. With ongoing projects and plans for commercial rollout, Semarion aims to revolutionize in vitro drug discovery and deliver groundbreaking solutions to the biopharma industry.
